This Blood report zooms in on a 78-year-old man with NPM1-mutated acute myeloid leukemia (AML) plus FLT3-ITD, a combo hematologists know can get messy fast. The weird part was not just that his leukemia came back. It came back looking like it could not decide whether it wanted to be granulocytic or monocytic - two related branches of the myeloid family tree, but still distinct enough that mixing their features can throw off routine diagnosis.
AML, at its core, is a cancer where immature blood cells pile up in the bone marrow and crowd out the normal stuff you actually need, like infection-fighting cells, red cells, and platelets. NPM1-mutated AML is one of the best-known genetic subtypes, and in many cases it has a recognizable look and behavior under the microscope and in molecular testing [1,2]. But "recognizable" is doing a lot of work there. Leukemia cells love a plot twist.
In this case, the marrow showed lots of large blasts, but flow cytometry - the lab method that sorts cells by their markers like a nightclub bouncer with a barcode scanner - put them in a granulocytic region, not the classic blast zone. That matters because a busy lab could miss or misread them if it only expects the usual pattern. The cells also expressed a baffling mix of signals: some pointing toward monocytic identity, others toward granulocytic identity. In plain English, the leukemia showed up wearing two jerseys at once.
The cell identity crisis nobody ordered
Why is that interesting? Because cancer is bad enough when it is obvious. It gets extra rude when it shape-shifts.
NPM1-mutated AML has long been recognized as its own biological entity, but researchers have learned that it is not one tidy disease in a neat little box [1-4]. Different co-mutations, different maturation states, and different immune-marker patterns can make cases behave differently. Othman and colleagues showed in 2024 that the outcomes in NPM1-mutated AML depend not just on the headline mutation, but also on the broader molecular cast, measurable residual disease, and treatment context [4]. Translation: the main character matters, but the supporting cast can still wreck the ending.
That is where this case earns its underdog stripes. It is not a 2,000-patient mega-trial with glossy survival curves and conference lighting. It is one oddball case saying, "Hey, maybe your leukemia gatekeeping strategy is too narrow." And sometimes that is exactly how medicine gets smarter - one annoying exception at a time.
Why this matters outside pathology nerdery
If leukemia cells can drift into an unusual phenotype, that affects more than academic bragging rights. It can change:
- how quickly the disease is recognized
- whether residual disease gets detected accurately
- how clinicians interpret relapse
- how confidently a patient gets matched to a treatment plan
That last part is a big deal. NPM1 mutations are especially useful because they can be tracked molecularly over time, almost like leaving fluorescent breadcrumbs through treatment [1,3]. But morphology and immunophenotype still matter, especially when the disease stops behaving like the textbook version. Falini and Dillon argued in 2024 that NPM1-mutated AML often demands a combined approach - molecular testing plus immunohistochemistry plus careful clinicopathologic judgment - precisely because tricky cases exist [3]. This paper is basically Exhibit A, wearing a fake mustache.
And there is a broader real-world backdrop here. As of October 24, 2025, the FDA approved revumenib for relapsed or refractory AML with a susceptible NPM1 mutation, a reminder that spotting this subtype correctly is not just classification trivia anymore - it increasingly points toward specific treatment options. When diagnosis gets more precise, therapy can get less medieval.
The underdog lesson
The sneaky value of this paper is that it champions the unloved middle ground between "obvious AML" and "what on earth is that?" It reminds clinicians that leukemias are not static trading cards. They evolve. They borrow traits. They confuse instruments. They make experts sigh into their coffee.
But if this weird hybrid phenotype becomes more widely recognized, fewer cases may slip past the usual blast gate, and fewer patients may have delays in getting the right diagnosis and the right next move. That is not flashy. It is better. It is the kind of quiet win medicine runs on.
Cancer, being the overachieving little menace that it is, keeps finding new ways to cheat. The useful response is not outrage - though fair enough - but sharper pattern recognition. This case hands us exactly that.
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.
References
-
Falini B, Brunetti L, Martelli MP. How I diagnose and treat NPM1-mutated AML. Blood. 2021;137(5):589-599. DOI: https://doi.org/10.1182/blood.2020008211
-
Patel SS. NPM1-Mutated Acute Myeloid Leukemia: Recent Developments and Open Questions. Acta Haematol. 2024;91(1):18-29. DOI: https://doi.org/10.1159/000530253. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC10857804/
-
Falini B, Dillon R. Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML. Blood Cancer Discovery. 2024;5(1):8-20. DOI: https://doi.org/10.1158/2643-3230.BCD-23-0144. PubMed: https://pubmed.ncbi.nlm.nih.gov/37917833/
-
Othman J, Potter N, Ivey A, et al. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML. Blood. 2024;144(7):714-728. DOI: https://doi.org/10.1182/blood.2024024310
-
Wang W, Fang H. NPM1-mutated acute myeloid leukemia with a hybrid granulocytic and monocytic phenotype. Blood. 2026;147(17):2019. DOI: https://doi.org/10.1182/blood.2025032818. PubMed: https://pubmed.ncbi.nlm.nih.gov/42024393/
-
FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. U.S. Food and Drug Administration. October 24, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation